The present invention discloses a method to reduce elevated blood glucose levels in a subject, typically having (pre-)diabetes, steatohepatitis, obesity, and/or metabolic syndrome, when orally administered. Particularly preferred compositions include a set of active components consisting of two or more isolated and purified saccharides selected from galacturonic acid, glucuronic acid, galactose, arabinose, glucuronic acid, rhamnose, xylose, and mannose. The composition administered to a subject in need thereof an effective dose of the composition for a period of at least 6 weeks, wherein administration results in an at least 5% reduction of blood glucose.
